Updated on 2025/06/18

Information

 

写真a

 
YASUNAGA MASAFUMI
 
Organization
Kyushu University Hospital Gynecology & Obstetrics Assistant Professor
School of Medicine Department of Medicine（Concurrent）
Title
Assistant Professor
Profile
助教講師としてレジデントの教育、育成に関与。 週2回程度の外来を行い20人/日程度の患者の診察を施行。また週1回程度の婦人科悪性腫瘍手術を執刀。 余った時間を利用して臨床データを取りまとめ、それについての論文作成に充てている。
External link

Degree

  • Anatomic Pathology

Research Interests・Research Keywords

  • Research theme： Decision making of subsequent therapy for recurrent or advanced endometrial cancer patients based on platinum-free interval

    Keyword： Recurrent endometrial cancer, chemotherapy, platinum sensitivity

    Research period： 2022.4 - 2023.4

  • Research theme： Analysis of risk factors related to recurrence and treatment failure of conservative management for atypical endometrial hyperplasia and endometrial carcinoma patients.

    Keyword： Endometrial cancer, hormonal therapy, recurrence

    Research period： 2017.6 - 2021.6

  • Research theme： Exprolatory study to detect the molecular markers for lymph nodes metastasis of uterine cervical cancer

    Keyword： Uterine cervical cancer, lymph nodes metastasis, molecular marker

    Research period： 2015.6 - 2021.6

Papers

  • Retrospective analysis of treatment and prognosis for clear cell carcinoma of the uterine cervix: 15-year experience at a single institution

    Inomata, Y; Kodama, K; Maenohara, S; Yagi, H; Yasunaga, M; Onoyama, I; Asanoma, K; Yahata, H; Oda, Y; Kato, K

    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH   51 ( 4 )   e16300   2025.4   （ ISSN:1341-8076 eISSN:1447-0756 ）

    　More details

    Language：English   Publisher：Journal of Obstetrics and Gynaecology Research  

    Aim: Clear cell carcinoma of the uterine cervix (CCCUC) is a rare disease, accounting for 4% to 9% of cervical adenocarcinomas. Because it is so rare, its pathogenesis is largely unknown, and the standard treatment is unclear due to a lack of prospective studies. Our aim is to investigate the clinical features, treatment, and prognosis of CCCUC. Methods: We retrospectively evaluated the clinical characteristics, treatment choices, and outcomes of 12 patients with CCCUC treated at our institution between January 2009 and July 2024. Results: The median patient age was 62.5 years (range, 14–90 years). The most common stage was IB (IA, n = 3; IB, n = 4; IIB, n = 1; IIIC, n = 2; IVB, n = 2). Ten patients underwent surgery as initial treatment: 6 underwent radical hysterectomy plus pelvic lymphadenectomy (PLD) or sentinel lymph node biopsy (SLNB), with or without para-aortic lymphadenectomy (PALD); 3 underwent modified radical hysterectomy plus PLD with or without PALD; and 1 underwent radical trachelectomy with SLNB as fertility-preserving surgery. All patients underwent bilateral salpingo-oophorectomy except for the patient who opted for radical trachelectomy. Five patients received adjuvant treatment: 3 received platinum-based systemic chemotherapy (2 of whom had combination therapy with bevacizumab), and 2 received concurrent chemoradiotherapy. The median follow-up was 43.5 months (range, 1–123 months). The 5-year progression-free survival rate was 64.5%. Conclusion: Systemic platinum-based chemotherapy with bevacizumab may be more effective than concurrent chemoradiotherapy as adjuvant therapy for CCCUC.

    DOI： 10.1111/jog.16300

    Web of Science

    Scopus

    PubMed

  • Low-Grade Endometrial Cancer with Abnormal p53 Expression as a Separate Clinical Entity: Insights from RNA Sequencing and Immunohistochemistry

    Hachisuga, K; Kawakami, M; Tomonobe, H; Maenohara, S; Kodama, K; Yagi, H; Yasunaga, M; Onoyama, I; Asanoma, K; Yahata, H; Oda, Y; Kato, K

    DIAGNOSTICS   15 ( 6 )   2025.3   （ ISSN:2075-4418 eISSN:2075-4418 ）

    　More details

    Language：English   Publisher：Diagnostics  

    Background: A molecular classification of endometrial cancer was developed based on an analysis of The Cancer Genome Atlas. In this classification, the group characterized by abnormal p53 immunohistochemical expression showed the poorest prognosis. However, there may be no need to apply a molecular classification in low-grade endometrial cancer. In this study, we investigated the clinical significance of abnormal p53 immunohistochemical expression in low-grade endometrial cancer. Methods: We obtained nine frozen samples of endometrial cancer [low-grade endometrial cancer with wild-type p53 expression (EC<sup>lo</sup>p53<sup>wt</sup> group): n = 3, low-grade endometrial cancer with abnormal p53 expression (EC<sup>lo</sup>p53<sup>ab</sup> group): n = 3, and high-grade endometrial cancer (EC<sup>hi</sup> group): n = 3]. RNA sequencing was performed for each sample. All the samples passed RNA quality control. In addition, an immunohistochemical analysis was performed for 44 formalin-fixed paraffin-embedded samples. Results: Differentially expressed genes were identified in the RNA sequencing results (1811 genes between the EC<sup>lo</sup>p53<sup>ab</sup> group and the EC<sup>hi</sup> group, and 1088 genes between the EC<sup>lo</sup>p53<sup>ab</sup> group and the EC<sup>lo</sup>p53<sup>wt</sup> group). In a principal component analysis, the EC<sup>lo</sup>p53<sup>ab</sup> group was more similar to the EC<sup>lo</sup>p53<sup>wt</sup> group than to the EC<sup>hi</sup> group. In the immunohistochemical analysis, L1CAM expression was significantly less frequently observed in the EC<sup>lo</sup>p53<sup>ab</sup> group than in the EC<sup>hi</sup> group. Moreover, p21 expression tended to be more frequently observed in the EC<sup>lo</sup>p53<sup>ab</sup> group than in the EC<sup>hi</sup> group. Conclusions: In this study, the RNA sequencing and immunohistochemical results revealed that the EC<sup>lo</sup>p53<sup>ab</sup> group is a separate entity from the EC<sup>hi</sup> group. While the abnormal p53 group is considered the most prognostically unfavorable in molecular classification, these findings suggest that routine molecular profiling is not necessary for patients with low-grade endometrial cancer. However, there is insufficient evidence to modify adjuvant treatment in low-grade endometrial cancer patients. Further investigation is needed on the clinical application of molecular classification to low-grade endometrial cancer.

    DOI： 10.3390/diagnostics15060671

    Web of Science

    Scopus

    PubMed

  • A treatment strategy for endometrial cancer focusing on KRAS mutation and DUSP6 expression

    Kawakami, M; Tomonobe, H; Hachisuga, K; Maenohara, S; Kodama, K; Yagi, H; Yasunaga, M; Onoyama, I; Asanoma, K; Yahata, H; Kato, K

    CANCER SCIENCE   116   1738 - 1738   2025.1   （ ISSN:1347-9032 eISSN:1349-7006 ）

    　More details

  • Sentinel Lymph Node Detection Using SPECT and Gamma Probe in Low-Risk Endometrial Cancer: Efficacy and Factors Associated With Detection Failure

    Asanoma, K; Yahata, H; Kodama, K; Okugawa, K; Yasunaga, M; Onoyama, I; Yagi, H; Maenohara, S; Hachisuga, K; Isoda, T; Shimokawa, M; Ishigami, K; Oda, Y; Kato, K

    ASIAN JOURNAL OF ENDOSCOPIC SURGERY   18 ( 1 )   e70015   2025.1   （ ISSN:1758-5902 eISSN:1758-5910 ）

    　More details

    Language：English   Publisher：Asian Journal of Endoscopic Surgery  

    Introduction: This study examined factors that affected sentinel lymph node (SLN) identification of patients with endometrial cancer having a preoperative estimation of low recurrent risk. Methods: This study included 97 patients with endometrial cancer who attempted to identify SLN using a uterine cervical injection of technetium-99 m phytate under laparoscopic or robotic-assisted surgery at our institute. A preoperative single photon emission computed tomography (SPECT) and intraoperative gamma probe were used to detect hot nodes. Multiple clinical factors, including age, body mass index (BMI), and so on, were investigated for their association with SLN mapping failure. Results: Among 97 cases, SPECT failed to detect SLN unilaterally in 38 cases (39%) and on both sides in 9 cases (9%). Meanwhile, the gamma probe failed to detect SLN unilaterally in 23 cases (24%) and on both sides in 3 cases (3%). While only age was significantly associated with SLN detection failure using the SPECT detection system, both age and BMI were significantly associated with SLN detection failure using the gamma probe detection system. When limiting to the preoperative SLN detection failure cohort of 47 cases, there was a strong association between intraoperative SLN detection failure and BMI, but not age. Conclusion: The SLN biopsy system was effectively applied to patients with endometrial cancer who underwent minimally invasive surgery (MIS). Attempts to improve SLN identification in older patients and those with obesity are warranted to obtain maximum benefits of MIS for low- or medium-risk cases.

    DOI： 10.1111/ases.70015

    Web of Science

    Scopus

    PubMed

  • Differences of initial DNA methylation alteration induced by RAS activation and PTEN loss

    Onoyama, I; Yagi, H; Asanoma, K; Kawakami, M; Hachisuga, K; Maenohara, S; Kodama, K; Yasunaga, M; Yahata, H; Kato, K

    CANCER SCIENCE   116   1131 - 1131   2025.1   （ ISSN:1347-9032 eISSN:1349-7006 ）

    　More details

  • Sentinel Lymph Node Detection Using SPECT and Gamma Probe in Low-Risk Endometrial Cancer: Efficacy and Factors Associated With Detection Failure(タイトル和訳中)

    Asanoma Kazuo, Yahata Hideaki, Kodama Keisuke, Okugawa Kaoru, Yasunaga Masafumi, Onoyama Ichiro, Yagi Hiroshi, Maenohara Shoji, Hachisuga Kazuhisa, Isoda Takuro, Shimokawa Mototsugu, Ishigami Kousei, Oda Yoshinao, Kato Kiyoko

    Asian Journal of Endoscopic Surgery   18 ( 1 )   ases.70015 - ases.70015   2025   （ ISSN:1758-5902 ）

    　More details

    Language：English   Publisher：John Wiley & Sons Australia, Ltd  

  • Clinical Significance of Tumor Immune Microenvironment in Endometrial Endometrioid Carcinoma, Grade 1 With DNA Mismatch Repair Protein Loss

    Hachisuga, K; Kawakami, M; Tomonobe, H; Maenohara, S; Kodama, K; Yagi, H; Yasunaga, M; Onoyama, I; Asanoma, K; Yahata, H; Oda, Y; Kato, K

    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY   43 ( 6 )   573 - 585   2024.11   （ ISSN:0277-1691 eISSN:1538-7151 ）

    　More details

    Publisher：International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists  

    The administration of immune checkpoint inhibitors (ICIs) is increasing in endometrial cancer, especially in the mismatch repair (MMR)-deficient group. To prevent unnecessary immune-related adverse events, ICIs need to be administered to more appropriate patients. The tumor immune microenvironment has been reported to be a predictive marker of the efficacy of ICI therapies. This study evaluated CD8, FoxP3, CD68, PD-L1, and β-catenin expression in endometrial endometrioid carcinoma, grade 1 (G1) with DNA mismatch repair protein loss (MMR loss), and their association with clinicopathological features. We retrospectively analyzed tumor samples from 107 patients with endometrial endometrioid carcinoma, G1 (MMR-deficient group: n=67; MMR-proficient group: n=40). Overall, 47 cases of MLH1/PMS2 loss and 20 cases of MSH2/MSH6 loss were observed. The patients with low intraepithelial CD8 expression significantly more frequently exhibited deep myometrial invasion, and the elderly group (≥60 y) significantly more frequently showed low stromal CD8 expression. In addition, FoxP3-positive cell count and FoxP3/CD8+ ratio were significantly correlated with the International Federation of Obstetrics and Gynecology 2023 stage and lymph node metastasis. In the Kaplan-Meier analysis, the patients with low intraepithelial or stromal CD8 expression had shorter progression-free survival (PFS) than those with high intraepithelial or stromal CD8 expression, albeit not significantly. We clarified that the tumor immune microenvironment had an impact on clinicopathological features within the group with MMR loss, which is the main target for ICIs, limited to endometrioid carcinoma, G1. Further studies are needed, including on patients administered ICIs.

    DOI： 10.1097/PGP.0000000000001020

    Web of Science

    Scopus

    PubMed

  • 術前補助化学療法後の巨大再発成人顆粒膜細胞腫に対して完全縮小手術を施行した1例(Complete reduction surgery of a huge recurrent adult granulosa cell tumor after neoadjuvant chemotherapy)

    Tokui Hiroha, Yahata Hideaki, Okabe Yasuhiro, Magarifuchi Naomi, Maenohara Shoji, Hachisuga Kazuhisa, Tomonobe Hiroshi, Kodama Keisuke, Yagi Hiroshi, Yasunaga Masafumi, Onoyama Ichiro, Asanoma Kazuo, Oda Yoshinao, Nakamura Masafumi, Kato Kiyoko

    International Cancer Conference Journal   13 ( 2 )   162 - 166   2024.4

    　More details

    Language：English   Publisher：シュプリンガー・ジャパン(株)  

    症例は72歳女性、2妊2産であった。卵巣悪性腫瘍に対して52歳時に開腹子宮全摘術、両側卵管卵巣摘出術、大網切除術、骨盤リンパ節郭清術を施行され、最終診断はステージIaの成人型顆粒膜細胞腫(AGCT)であった。初回手術から19年後、他施設で受けたCTで後腹膜腫瘍が偶然発見された。腫瘍は直径11×10cmで、肝門部、下大静脈、右腎静脈が隆起していた。CTガイド下腫瘍生検によりAGCTの再発が確認された。腫瘍が巨大であり、完全切除を行うと出血多量による術中死亡のリスクがあると考えられた。そこで、パクリタキセル+カルボプラチン(PC)による術前化学療法を行い、再発腫瘍を縮小させた。その後、縮小手術を行った。再発腫瘍の完全切除に成功し、手術時間は12時間54分、出血量は700gであった。切除標本の病理所見からAGCTの再発と診断した。術後1年経過時点で再発は認められなかった。

  • Complete reduction surgery of a huge recurrent adult granulosa cell tumor after neoadjuvant chemotherapy

    Tokui, H; Yahata, H; Okabe, Y; Magarifuchi, N; Maenohara, S; Hachisuga, K; Tomonobe, H; Kodama, K; Yagi, H; Yasunaga, M; Onoyama, I; Asanoma, K; Oda, Y; Nakamura, M; Kato, K

    INTERNATIONAL CANCER CONFERENCE JOURNAL   13 ( 2 )   162 - 166   2024.4   （ ISSN:2192-3183 ）

    　More details

  • The BHLHE40‒PPM1F‒AMPK pathway regulates energy metabolism and is associated with the aggressiveness of endometrial cancer

    Asanoma K., Yagi H., Onoyama I., Cui L., Hori E., Kawakami M., Maenohara S., Hachisuga K., Tomonobe H., Kodama K., Yasunaga M., Ohgami T., Okugawa K., Yahata H., Kitao H., Kato K.

    Journal of Biological Chemistry   300 ( 3 )   105695   2024.3   （ ISSN:00219258 eISSN:1083-351X ）

    　More details

    Language：English   Publisher：Journal of Biological Chemistry  

    BHLHE40 is a basic helix-loop-helix transcription factor that is involved in multiple cell activities including differentiation, cell cycle, and epithelial-to-mesenchymal transition. While there is growing evidence to support the functions of BHLHE40 in energy metabolism, little is known about the mechanism. In this study, we found that BHLHE40 expression was downregulated in cases of endometrial cancer of higher grade and advanced disease. Knockdown of BHLHE40 in endometrial cancer cells resulted in suppressed oxygen consumption and enhanced extracellular acidification. Suppressed pyruvate dehydrogenase (PDH) activity and enhanced lactated dehydrogenase (LDH) activity were observed in the knockdown cells. Knockdown of BHLHE40 also led to dephosphorylation of AMPKα Thr172 and enhanced phosphorylation of pyruvate dehydrogenase E1 subunit alpha 1 (PDHA1) Ser293 and lactate dehydrogenase A (LDHA) Tyr10. These results suggested that BHLHE40 modulates PDH and LDH activity by regulating the phosphorylation status of PDHA1 and LDHA. We found that BHLHE40 enhanced AMPKα phosphorylation by directly suppressing the transcription of an AMPKα-specific phosphatase, PPM1F. Our immunohistochemical study showed that the expression of BHLHE40, PPM1F, and phosphorylated AMPKα correlated with the prognosis of endometrial cancer patients. Because AMPK is a central regulator of energy metabolism in cancer cells, targeting the BHLHE40‒PPM1F‒AMPK axis may represent a strategy to control cancer development.

    DOI： 10.1016/j.jbc.2024.105695

    Web of Science

    Scopus

    PubMed

  • Development of novel tracers for sentinel node identification in cervical cancer

    Kodama Keisuke, Tateishi Chuya, Oda Tsuyoshi, Cui Lin, Kuramoto Kazutaka, Yahata Hideaki, Okugawa Kaoru, Maenohara Shoji, Yagi Hiroshi, Yasunaga Masafumi, Onoyama Ichiro, Asanoma Kazuo, Mori Takeshi, Katayama Yoshiki, Kato Kiyoko

    Cancer Science   114 ( 11 )   4216 - 4224   2023.11   （ ISSN:13479032 eISSN:13497006 ）

    　More details

    Language：English   Publisher：Wiley  

    Indocyanine green (ICG) with near-infrared (NIR) fluorescence imaging is used for lymphatic mapping. However, binding of ICG to blood proteins like serum albumin can shorten its retention time in sentinel lymph nodes (SLNs). Here, we investigated the efficacy and safety of a new fluorescence tracer comprising phytate and liposome (LP)-encapsulated ICG. Coadministration of phytate with LP containing phosphatidic acid promotes chelation mediated by Ca^<2+> in bodily fluids to enhance SLN retention. Uniformly sized LPs (100 nm) encapsulating ICG under conditions that minimized fluorescence self-quenching during storage were produced. We analyzed the behavior of the new tracer (ICG-phytate-LP) and control tracers (ICG and ICG-LP) in the lymphatic flow of mice in terms of lymph node retention time. We also tested lymphatic flow and safety in pigs that have a more human-like lymphatic system. LPs encapsulating stabilized ICG were successfully prepared. Mixing LP with phytate in the presence of Ca^<2+> increased both the particle size and negative surface charge. In mice, ICG-phytate-LP had the best lymph node retention, with a fluorescence intensity ratio that increased over 6 h and then decreased slowly over the next 24 h. In pigs, administration of ICG and ICG-phytate-LP resulted in no death or weight loss. There were no obvious differences between blood test results for the ICG and ICG-phytate-LP groups, and the overall safety was good. ICG-phytate-LP may be a useful new tracer for gynecological cancers that require time for lymph node identification due to a retroperitoneal approach.

    DOI： 10.1111/cas.15927

    Web of Science

    Scopus

    PubMed

    CiNii Research

  • 子宮頸癌例でのセンチネルリンパ節同定に用いる新規トレーサーの開発(Development of novel tracers for sentinel node identification in cervical cancer)

    Kodama Keisuke, Tateishi Chuya, Oda Tsuyoshi, Cui Lin, Kuramoto Kazutaka, Yahata Hideaki, Okugawa Kaoru, Maenohara Shoji, Yagi Hiroshi, Yasunaga Masafumi, Onoyama Ichiro, Asanoma Kazuo, Mori Takeshi, Katayama Yoshiki, Kato Kiyoko

    Cancer Science   114 ( 11 )   4216 - 4224   2023.11   （ ISSN:1347-9032 ）

    　More details

    Language：English   Publisher：John Wiley & Sons Australia, Ltd  

    センチネルリンパ節(SLN)を同定するためのトレーサーとして、リポソーム封入インドシアニングリーン(ICG)とフィチン酸塩で構成される新規な蛍光トレーサーを開発し、その有効性と安全性を調査した。まず、安定化したICGが封入されているリポソームを調製した。次にキレート反応が発揮されることを期待し、Ca2+の存在下でリポソームとフィチン酸塩を混和した。その結果、生成される粒子のサイズとその表面の陰電荷が共に増加した。このようにICG、リポソーム、フィチン酸塩を構成要素とした新規トレーサーがマウスのリンパ節内に滞留する時間を評価した。その結果、対照のトレーサー(ICGおよびリポソーム封入ICG)と比較して最も良好な滞留性を発揮した。その蛍光強度比は6時間かけて上昇し、次いで24時間かけて緩やかに低下していった。ブタで安全性評価を行ったが、本新規トレーサーを投与しても死亡または体重減少は発生しなかった。ICGのみ投与した場合との明確な違いも示されず、全安全性は良好であった。本新規トレーサーは、後腹膜アプローチのためリンパ節を同定する時間が必要になる婦人科癌で有用なものになると考えられた。

  • Secondary Adrenal Insufficiency Due to Isolated ACTH Deficiency Induced by Pembrolizumab: A Report of Two Cases of Uterine Endometrial Cancer

    Onoyama, I; Kawakami, M; Hachisuga, K; Maenohara, S; Kodama, K; Yagi, H; Yasunaga, M; Ohgami, T; Asanoma, K; Yahata, H; Kitamura, Y; Sakamoto, R; Kiyozawa, D; Kato, K

    REPORTS   6 ( 2 )   2023.6   （ eISSN:2571-841X ）

    　More details

  • An update of oncologic and obstetric outcomes after abdominal trachelectomy using the FIGO 2018 staging system for cervical cancer: a single-institution retrospective analysis Reviewed International journal

    Kaoru Okugawa, Hideaki Yahata, Tatsuhiro Ohgami, Masafumi Yasunaga, Kazuo Asanoma, Hiroaki Kobayashi, Kiyoko Kato

    J Gynecol Oncol   2023.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Decision-making for Subsequent Therapy for Patients With Recurrent or Advanced Endometrial Cancer Based on the Platinum-free Interval Reviewed International journal

    Masafumi Yasunaga, Hideaki Yahata, Kaoru Okugawa, Emiko Hori, Kazuhisa Hachisuga, Shoji Maenohara, Keisuke Kodama, Hiroshi Yagi, Tatsuhiro Ohgami, Ichiro Onoyama, Kazuo Asanoma, and Kiyoko Kato

    American Journal of Clinical Oncology   46 ( 9 )   387 - 391   2023.5   （ ISSN:0277-3732 eISSN:1537-453X ）

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：American Journal of Clinical Oncology: Cancer Clinical Trials  

    Objective: The aim of this study was to evaluate the progression-free survival (PFS) and overall response rate (ORR) of patients with recurrent endometrial cancer (REC) or advanced endometrial cancer (AEC) retreated with platinum-containing chemotherapy (PCC) based on the platinum-free interval (PFI). We compared our results with those reported in the KEYNOTE-775 study (that used pembrolizumab plus lenvatinib). Methods: A retrospective analysis was conducted of 65 patients with REC or AEC retreated with PCC between 2005 and 2020 at our hospital. Various clinicopathologic variables were analyzed: (1) age, (2) performance status, (3) histology, (4) history of pelvic irradiation in the adjuvant setting, (5) PFI, (6) chemotherapy regimen, (7) PFS and overall survival after retreatment with PCC, and (8) best ORR. Survival analyses were performed using Kaplan-Meier curves and log-rank tests. Results: The best ORR and PFS were 43.3% and 9.5 months, respectively, in patients with REC/AEC with a PFI ≥6 months. These results were comparable with those of patients treated with pembrolizumab and lenvatinib. The best ORR and PFS of patients with a PFI of <6 months appeared to be inferior to those of patients treated with pembrolizumab plus lenvatinib. Conclusions: Pembrolizumab plus lenvatinib seems to be a better treatment choice for patients with REC or AEC with a PFI of <6 months. For a PFI of ≥6 months, pembrolizumab plus lenvatinib or PCC can be used depending on the degree of residual side -effects associated with cytotoxic agents.

    DOI： 10.1097/COC.0000000000001021

    Web of Science

    Scopus

    PubMed

  • Tumor-derived ARHGAP35 mutations enhance the Gα<sub>13</sub>-Rho signaling axis in human endometrial cancer

    Yagi, H; Onoyama, I; Asanoma, K; Kawakami, M; Maenohara, S; Kodama, K; Matsumura, Y; Hamada, N; Hori, E; Hachisuga, K; Yasunaga, M; Ohgami, T; Okugawa, K; Yahata, H; Kato, K

    CANCER GENE THERAPY   30 ( 2 )   313 - 323   2023.2   （ ISSN:0929-1903 eISSN:1476-5500 ）

    　More details

    Language：English   Publisher：Cancer Gene Therapy  

    Dysregulated G protein-coupled receptor signaling is involved in the formation and progression of human cancers. The heterotrimeric G protein Gα13 is highly expressed in various cancers and regulates diverse cancer-related transcriptional networks and cellular functions by activating Rho. Herein, we demonstrate that increased expression of Gα13 promotes cell proliferation through activation of Rho and the transcription factor AP-1 in human endometrial cancer. Of interest, the RhoGTPase activating protein (RhoGAP), ARHGAP35 is frequently mutated in human endometrial cancers. Among the 509 endometrial cancer samples in The Cancer Genome Atlas database, 108 harbor 152 mutations at 126 different positions within ARHGAP35, representing a somatic mutation frequency of 20.2%. We evaluated the effect of 124 tumor-derived ARHGAP35 mutations on Gα13-mediated Rho and AP-1 activation. The RhoGAP activity of ARHGAP35 was impaired by 55 of 124 tumor-derived mutations, comprised of 23 nonsense, 15 frame-shift, 15 missense mutations, and two in-frame deletions. Considering that ARHGAP35 is mutated in >2% of all tumors, it ranks among the top 30 most significantly mutated genes in human cancer. Our data suggest potential roles of ARHGAP35 as an oncogenic driver gene, providing novel therapeutic opportunities for endometrial cancer.

    DOI： 10.1038/s41417-022-00547-1

    Web of Science

    Scopus

    PubMed

  • 子宮体癌再発を疑った大網放線菌症の1例 Reviewed

    清武　早紀、安永　昌史、蜂須賀　一寿、安武　伸子、前之原　章司、八木　裕史、大神　達寛、小野山　一郎、奥川　馨、淺野間　和夫、矢幡　秀昭、加藤　聖子

    福岡産科婦人科学会雑誌   2023.1

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • 子宮体癌再発を疑った大網放線菌症の1例

    清武 早紀, 安永 昌史, 蜂須賀 一寿, 安武 伸子, 前之原 章司, 八木 裕史, 大神 達寛, 小野山 一郎, 奥川 馨, 淺野間 和夫, 矢幡 秀昭, 加藤 聖子

    福岡産科婦人科学会雑誌   46 ( 2 )   18 - 22   2023.1   （ ISSN:2187-7211 ）

    　More details

    Language：Japanese   Publisher：福岡産科婦人科学会  

    症例は76歳、3妊3産。不正性器出血を主訴に前医を受診し、子宮内膜肥厚を認め、精査加療目的に当科を紹介受診した。当科の子宮内膜全面掻爬にて子宮内膜異型増殖症の診断で、全腹腔鏡下単純子宮全摘出術+両側付属器摘出術を施行した。最終診断は子宮体癌IA期、類内膜癌G1の診断で、再発低リスク群であり、追加治療は施行せず経過観察とした。2年後の造影CT検査で大網左側に結節状の軟部陰影と周囲脂肪織混濁を認め再発が疑われた。CTガイド下生検を施行し、病理組織検査で非特異的な炎症所見を認めるのみで、悪性所見は認めなかった。更に1年後のCTで軟部陰影は増大傾向であり、子宮体癌再発の可能性も否定できず、診断確定目的に大網部分切除術を施行した。最終病理組織診断の結果は放線菌症の診断であった。放線菌症は悪性腫瘍との鑑別が難しいため、非典型的な臨床経過の場合は放線菌感染も鑑別の一つとして念頭においておくべきと思われた。(著者抄録)

  • ステージIAの再発リスクの低い子宮内膜癌患者において肥満がロボット支援手術に及ぼす影響　施設研究(Impact of obesity on robotic-assisted surgery in patients with stage IA endometrial cancer and a low risk of recurrence: An institutional study)

    Asanoma Kazuo, Yahata Hideaki, Okugawa Kaoru, Ohgami Tatsuhiro, Yasunaga Masafumi, Kodama Keisuke, Onoyama Ichiro, Kenjo Hironori, Shimokawa Mototsugu, Kato Kiyoko

    The Journal of Obstetrics and Gynaecology Research   48 ( 12 )   3226 - 3232   2022.12   （ ISSN:1341-8076 ）

    　More details

    Language：English   Publisher：John Wiley & Sons Australia, Ltd  

    ロボット支援手術が施行された子宮内膜癌患者63例を対象とした後向きコホート研究を実施し、肥満がロボット支援手術の安全性および質に及ぼす影響について検討した。患者を非肥満群40例(BMI:30未満、中央値54歳)、肥満群13例(BMI:30以上35未満、中央値54歳)、病的肥満10例(BMI;35以上、中央値50歳)に分類した。評価項目は手術時間、出血量、周術期合併症、再発率とした。その結果、開腹術への移行は非肥満群1例、病的肥満群1例であった。総手術時間、セッティング時間(トロッカー留置、ダヴィンチロボットドッキングを含む)、コンソール時間、創部閉鎖時間に群間差は認められなかったが、セッティングおよび創部閉鎖の合計時間に群間差が認められた。出血量や合併症には群間差が認められた。非肥満群3例、肥満群2例に対して、術後補助療法が実施されたが、平均観察期間21ヵ月において再発は認められなかった。非肥満群2例、肥満群1例が平均観察期間38ヵ月に再発していた。以上から、肥満を呈する子宮内膜癌患者に対するロボット支援手術の安全性が示された。

  • Tumor-derived ARHGAP35 mutations enhance the Gα13-Rho signaling axis in human endometrial cancer Invited Reviewed International journal

    Hiroshi Yagi, Ichiro Onoyama, Kazuo Asanoma, Minoru Kawakami, Shoji Maenohara, Keisuke Kodama, Yumiko Matsumura, Norio Hamada , Emiko Hori, Kazuhisa Hachisuga, Masafumi Yasunaga, Tatsuhiro Ohgami, Kaoru Okugawa, Hideaki Yahata and Kiyoko Kato

    Cancer Gene Therapy   2022.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Impact of obesity on robotic-assisted surgery in patients with stage IA endometrial cancer and a low risk of recurrence: An institutional study Invited Reviewed International journal

    Kazuo Asanoma, Hideaki Yahata, Kaoru Okugawa, Tatsuhiro Ohgami, Masafumi Yasunaga, Keisuke Kodama, Ichiro Onoyama, Hironori Kenjo, Mototsugu Shimokawa and Kiyoko Kato

    The journal of Obstetrics and Gynaecology Research   2022.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer Reviewed International journal

    Masafumi Yasunaga, Hideaki Yahata, Kaoru Okugawa, Mototsugu Shimokawa,Yumiko Maeda, Emiko Hori, Keisuke Kodama, Hiroshi Yagi, Tatsuhiro Ohgami, Ichiro Onoyama, Kazuo Asanoma, Kiyoko Kato

    Taiwanese Journal of Obstetrics & Gynecology   2022.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • 再発子宮頸癌に対するペムブロリズマブ療法中に内腸骨動脈-S状結腸瘻を生じた一例(Arterio-enteric fistula in a patient with recurrent cervical cancer treated with pembrolizumab)

    永谷 優華, 八木 裕史, 久保 雄一郎, 牛島 泰宏, 堀 絵美子, 川上 穣, 友延 寛, 安武 伸子, 吉田 祥子, 小玉 敬亮, 安永 昌史, 大神 達寛, 小野山 一郎, 奥川 馨, 淺野間 和夫, 谷口 秀一, 嶋本 富博, 矢幡 秀昭, 石神 康生, 加藤 聖子

    宮崎県医師会医学会誌   46 ( 2 )   147 - 153   2022.9   （ ISSN:0389-8288 ）

    　More details

    Language：English   Publisher：(公社)宮崎県医師会  

    動脈-腸管瘻は消化管出血の原因としてはまれであるが,初発症状が致死性の大量出血の場合もある緊急性の高い疾患である。症例は44歳,9妊7産,子宮頸癌IB3期(扁平上皮癌)に対して広汎子宮全摘出術,両側付属器摘出術,術後補助療法として同時化学放射線療法を施行した。治療終了6ヵ月後に骨盤内再発を認め,全身化学療法を施行したが奏効しなかった。MSI検査の結果,MSI-highであったためペムブロリズマブ療法を開始した。腫瘍の著明な縮小を認め,4コース後の治療効果判定はPRであった。ペムブロリズマブ療法4コース目day7,当科入院中に突然,多量の下血,意識レベルの低下を認めた。緊急造影CTの結果,左内腸骨動脈からS状結腸への造影剤の漏出を認め,左内腸骨動脈-S状結腸瘻と診断した。直ちに左内腸骨動脈塞栓術を施行し止血した。発症から止血まで3時間の間に赤血球32単位,新鮮凍結血漿28単位,血小板10単位の輸血を要した。(著者抄録)

  • Long-term follow up after sentinel node biopsy alone for early-stage cervical cancer

    Yahata, H; Kodama, K; Okugawa, K; Hachisuga, K; Yasutake, N; Maenohara, S; Yagi, H; Yasunaga, M; Ohgami, T; Onoyama, I; Asanoma, K; Kobayashi, H; Sonoda, K; Baba, S; Ishigami, K; Ohishi, Y; Oda, Y; Kato, K

    GYNECOLOGIC ONCOLOGY   165 ( 1 )   149 - 154   2022.4   （ ISSN:0090-8258 eISSN:1095-6859 ）

    　More details

    Language：English   Publisher：Gynecologic Oncology  

    Objective: Sentinel node biopsy alone (SNB) reduces the postoperative complications of pelvic lymphadenectomy, such as lymphedema and lymphangitis; however, the long-term prognosis after SNB is unclear. The objective of this study was to evaluate the long-term outcome and complications of patients with early-stage cervical cancer who underwent SNB for hysterectomy or trachelectomy. Methods: We performed SNB for cervical cancer using a radioisotope method in 181 patients between 2009 and 2017. If the intraoperative sentinel lymph node evaluation was negative for metastasis, no further lymph nodes were removed. Results: The median age of the patients was 34 years (range, 21–73 years). The International Federation of Gynecology and Obstetrics 2008 stage was IA1 in 6 patients, IA2 in 18, IB1 in 154, and IIA1 in 3. Of the 181 patients (44 with hysterectomy, 137 with trachelectomy), 8 did not undergo pelvic lymphadenectomy because of a false-negative intraoperative diagnosis, 20 received adjuvant therapy after surgery, and 4 (2.2%) experienced recurrence over a median follow-up period of 83.5 months (range, 25–145 months). In the four recurrent cases, recurrence occurred in the pelvis, lung, and bone in one patient each, while the remaining patient developed pelvic and para-aortic lymph node metastases. Of these four patients, one died, and the remaining three are alive without disease after multidisciplinary therapy. The 5-year progression-free and overall survival rates were 98.8% and 99.4%, respectively. Postoperative complications, such as lymphedema, were very low rate. Conclusions: SNB for early-stage cervical cancer might be safe and effective, with no increase in the recurrence and postoperative complications rate.

    DOI： 10.1016/j.ygyno.2022.01.031

    Web of Science

    Scopus

    PubMed

  • A Case of Malignant Phyllodes Tumor of the Breast Metastasizing to the Ovary Reviewed International journal

    Yukiko Tada, MD, Masafumi Yasunaga, MD, PhD, Hiroshi Tomonobe, MD, Yuichi Yamada, MD, PhD, Emiko Hori, Kaoru Okugawa, MD, PhD, Hideaki Yahata, MD, Ph, Yoshinao Oda, MD, PhD, and Kiyoko Kato, MD, PhD1

    International Journal of Surgical Pathology   30 ( 4 )   427 - 431   2021.12   （ ISSN:1066-8969 eISSN:1940-2465 ）

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：International Journal of Surgical Pathology  

    Phyllodes tumors of the breast are uncommon, and 6.2% of phyllodes tumors behave in a malignant fashion. The metastatic spread of malignant phyllodes tumor is mainly hematogenous to lung and bone, and malignant phyllodes tumor metastasizing to the ovary is rare, with only 2 cases reported. We report the third case of metastatic malignant phyllodes tumor to the ovary with a focus on the differential diagnosis of ovarian cancer.

    DOI： 10.1177/10668969211056912

    Web of Science

    Scopus

    PubMed

  • Evaluation of Clinical Significance of Lymphovascular Space Invasion in Stage IA Endometrial Cancer Reviewed International journal

    Kaoru Okugawa, Hideaki Yahata, Kazuhisa Hachisuga, Hiroshi Tomonobe, Nobuko Yasutake. Keisuke Kodama, Hironori Kenjo, Hiroshi Yagi, Tatsuhiro Ohgami, Masafumi Yasunaga, Ichiro Onoyama, Kazuo Asanoma, Emiko Hori, Yoshihiro Ohishi, Yoshinao Oda, Kiyoko Kato

    Oncology   100 ( 4 )   195 - 202   2021.10   （ ISSN:0030-2414 eISSN:1423-0232 ）

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Oncology (Switzerland)  

    Introduction: The prognostic significance of lymphovascular space invasion (LVSI) in stage IA endometrial cancer remains unclear. The aim of this study was to evaluate the clinical significance of LVSI in stage IA endometrial cancer. Methods: Clinical data of patients with stage IA endometrial cancer who underwent initial surgery at our institution between January 2008 and December 2018 were reviewed retrospectively. Information of patients, surgery, and characteristics of cancer were obtained from medical records and pathological reports. Results: Two hundred ninety-seven patients were enrolled in this study. With a median follow-up of 60 months, 15 patients experienced recurrence (5.1%) and 4 patients died of endometrial cancer (1.3%). The recurrence and mortality rates did not differ significantly between the LVSI-positive and-negative groups (p = 0.07 and p = 0.41, respectively). Recurrence-free survival and endometrial cancer-specific survival also did not differ significantly between these groups (p = 0.11 and p = 0.49, respectively). The 5-year endometrial cancer-specific survival rates for tumors with and without LVSI were 97.0% and 98.9%, respectively. Among patients with low-grade tumors, recurrence-free survival and endometrial cancer-specific survival did not differ significantly between patients with tumors with and without LVSI (p = 0.92 and p = 0.72, respectively). The 5-year endometrial cancer-specific survival rates for low-grade tumors with and without LVSI were 100% and 99.3%, respectively. Conclusion: LVSI was not a prognostic factor of not only stage IA endometrial cancer but also stage IA low-grade cancer.

    DOI： 10.1159/000521382

    Web of Science

    Scopus

    PubMed

  • Prognostic impact of the subclassification of Müllerian cancer stage IV in the FIGO 2014 staging system with a focus of extra-abdominal lymph node metastases Reviewed International journal

    Masafumi Yasunaga, Hideaki Yahata, Kaoru Okugawa, Emiko Hori, Keisuke Kodama, Hiroshi Yagi, Tatsuhiro Ohgami, Ichiro Onoyama, Kazuo Asanoma, Kiyoko Kato

    Int J Clin Oncol   2021.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Hypersensitivity reaction to pegylated liposomal doxorubicin administration for Mullerian carcinoma in Japanese women Reviewed International journal

    Shinichiro Yamaguci, Hideaki Yahata, Kaoru Okugawa, Keisuke Kodama, Hiroshi Yagi, Masafumi Yasunaga, Tatsuhiro Ohgami, Ichiro Onoyama, Kazuo Asanoma, Kiyoko Kato

    Journal of Obstetrics and Gynaecology Research   2021.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Prognostic outcome and risk factors for recurrence after laser vaporization for cervical intraepithelial neoplasia: a single-center retrospective study Reviewed International journal

    Keisuke Kodama, Hideaki Yahata, Kaoru Okugawa, Hiroshi Tomonobe, Nobuko Yasutake, Sachiko Yoshida, Hiroshi Yagi, Masafumi Yasunaga, Tatsuhiro Ohgami, Ichiro Onoyama, Kazuo Asanoma, Emiko Hori, Mototsugu Shimokawa, Kiyoko Kato

    Int J Clin Oncol   2021.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Identification of genes associated with endometrial cell aging Reviewed International journal

    Teruhiko Kawamura, Hiroyuki Tomari, Ichiro Onoyama, Hiromitsu Araki, Masafumi Yasunaga, Cui Lin, Keiko Kawamura, Natsuko Yokota, Sachiko Yoshida, Hiroshi Yagi, Kazuo Asanoma, Kenzo Sonoda, Katsuko Egashira, Takashi Ito, Kiyoko Kato

    Molecular Human Reproduction   2020.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Is Adjuvant Therapy Necessary for Patients with Intermediate-Risk Cervical Cancer after Open Radical Hysterectomy? Reviewed International journal

    Hideaki Yahata, Kenzo Sonoda, Shusaku Inoue, Nobuko Yasutake, Keisuke Kodama, Hiroshi Yagi, Masafumi Yasunaga, Tatsuhiro Ohgami, Ichiro Onoyama, Eisuke Kaneki, Kaoru Okugawa, Kazuo Asanoma, Kiyoko Kato

    Oncology   2020.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Evaluation of adjuvant chemotherapy after abdominal trachelectomy for cervical cancer: a single-institution experience Reviewed International journal

    Kaoru Okugawa, Hideaki Yahata, Kenzo Sonoda, Hiroshi Yagi, Tatsuhiro Ohgami, Masafumi Yasunaga, Ichiro Onoyama, Eisuke Kaneki, Kazuo Asanoma, Hiroaki Kobayashi, Kiyoko Kato

    Int J Clin Oncol   2020.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • 腹腔鏡下前方骨盤除臓術を施行した外陰悪性黒色腫の一例 Laparoscopic anterior pelvic exenteration for vulvar malignant melanoma: A case report Reviewed

    安永　昌史, 矢幡　秀昭, 小玉　敬亮, 八木　裕史, 大神　達寛, 小野山　一郎,兼城　英輔, 奥川　馨,淺野間　和夫, 塩田　真己, 武内　在雄, 江藤　正俊, 加藤　聖子

    福岡産科婦人科学会雑誌   2020.7

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • Safety evaluation of abdominal trachelectomy in patients with cervical tumors ≥2 cm: a single-institution, retrospective analysis Reviewed International journal

    Kaoru Okugawa, Hideaki Yahata, Kenzo Sonoda, Tatsuhiro Ohgami, Masafumi Yasunaga, Eisuke Kaneki, Kiyoko Kato

    J Gynecol Oncol   2020.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • 子宮頸癌に対する腹腔鏡下広汎子宮全摘出術および腹式広汎子宮全摘出術症例の比較検討 Reviewed

    貴島 雅子, 堀 絵美子, 小玉 敬亮, 権丈 洋徳, 安永 昌史, 兼城 英輔, 矢幡 秀昭, 加藤 聖子

    日本産科婦人科内視鏡学会雑誌   2019.12

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • Survey of the desire to have children and engage in sexual activity after trachelectomy among young Japanese women with early-stage cervical cancer Reviewed International journal

    Yahata H, Sonoda K, Okugawa K, Yagi H, Ohgami T, Yasunaga M, Onoyama I, Kaneki E, Asanoma K, Kato K

    J Obstet Gynaecol Res   2019.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • 鏡視下手術におけるRadioisotope法を用いた子宮頸癌センチネルリンパ節同定法の有用性の検討 Reviewed

    矢幡 秀昭, 権丈 洋徳, 堀 絵美子, 貴島 雅子, 小玉 敬亮, 磯邊 明子, 八木 裕史, 大神 達寛, 安永 昌史, 小野山 一郎, 兼城 英輔, 奥川 馨, 淺野間 和夫, 加藤 聖子

    九州臨床外科医学会々誌   2019.11

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • Retrospective Analysis of Treatment and Prognosis for Uterine Leiomyosarcoma: 10-year Experience of a Single Institute Invited Reviewed International journal

    Kodama K, Sonoda K, Kijima M, Yamaguchi S, Yagi H , Yasunaga M, Ohgami T, Onoyama I, Kaneki E, Okugawa K, Yahata H, Ohishi Y , Oda Y, Kato K

    Asia Pac J Clin Oncol   2019.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Gα13-mediated LATS1 down-regulation contributes to epithelial-mesenchymal transition in ovarian cancer Reviewed International journal

    Yagi H, Onoyama I, Asanoma K, Hori E, Yasunaga M, Kodama K, Kijima M, Ohgami T, Kaneki E, Okugawa K, Yahata H, Kato K

    FASEB J   2019.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Mutual suppression between BHLHE40/BHLHE41 and the MIR301B-MIR130B cluster is involved in epithelial-to-mesenchymal transition of endometrial cancer cells Reviewed International journal

    Asanoma K, Hori E, Yoshida S, Yagi H, Onoyama I, Kodama K, Yasunaga M, Ohgami T, Kaneki E, Okugawa K, Yahata H, Kato K

    Oncotarget   2019.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Pelvic abscess: A late complication of abdominal trachelectomy for cervical cancer Reviewed International journal

    Okugawa K, Sonoda K, Ohgami T, Yasunaga M, Kaneki E, Yahata H, Kato K

    J Obstet Gynaecol Res   2019.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Prognostic outcome and complications of sentinel lymph node navigation surgery for early-stage cervical cancer Invited Reviewed International journal

    Yahata H, Kobayashi H, Sonoda K, Kodama K, Yagi H, Yasunaga M, Ohgami T, Onoyama I, Kaneki E, Okugawa K, Baba S, Isoda T, Ohishi Y, Oda Y, Kato K.

    Int J Clin Oncol   2018.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Value of Intraoperative Cytological and Pathological Sentinel Lymph Node Diagnosis in Fertility-Sparing Trachelectomy for Early-Stage Cervical Cancer. Invited Reviewed International journal

    Sonoda K, Yahata H, Okugawa K, Kaneki E, Ohgami T, Yasunaga M, Baba S, Oda Y, Honda H, Kato K.

    Oncology   2018.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Two types of small cell carcinoma of the ovary: Two typical case reports. Invited Reviewed International journal

    Yoshida Y, Kaneki E, Kijima M, Kodama K, Yamaguchi S, Yagi H, Yasunaga M, Ohgami T, Onoyama I, Okugawa K, Yahata H, Sonoda K, Kato K.

    Gynecol Oncol Rep   2018.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Surgical treatment and outcome of early invasive adenocarcinoma of the uterine cervix (FIGO stage IA1). Invited Reviewed International journal

    Yahata H, Sonoda K, Yasunaga M, Ohgami T, Kawano Y, Kaneki E, Okugawa K, Kaku T, Kato K.

    Asia Pac J Clin Oncol   2018.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • 腹腔鏡下に治療し得た腹膜妊娠の4症例 Reviewed

    山本　奈里、竹内　麗子、井槌　大介、弓削　乃利人、宮崎　順秀、安永　昌史、江頭　活子、上岡　洋介、井上　善仁

    日本産科婦人科内視鏡学会雑誌   29 ( 1 )   141 - 147   2013.11

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • Hysteroscopic adhesiolysis for patients with Asherman’s syndrome: menstrual and fertility outcomes Invited Reviewed International journal

    Nari Yamamoto • Reiko Takeuchi • Daisuke Izuchi • Norihito Yuge • Masahide Miyazaki • Masafumi Yasunaga • Katsuko Egashira • Yousuke Ueoka • Yoshihito Inoue

    Reproductive Medicine and Biology   12   159 - 166   2013.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Dedifferentiated chondrosarcoma arising in a mature cystic teratoma of the ovary: a case report and review of the literature Reviewed International journal

    Masafumi Yasunaga, MD, PhD, Toshiaki Saito, MD, PhD, Takako Eto, MD, Masao Okadome, MD, PhD, Kazuya Ariyoshi, MD, PhD, Ken-ichi Nishiyama, MD, PhD, Yoshinao Oda, MD, PhD

    International Journal of Gynecolgic Pathology   2011.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Expression and localization of E-cadherin and β-catenin in uterine carcinosarcoma. Invited Reviewed International journal

    Nishimura I, Ohishi Y, Oda Y, Kishimoto J, Yasunaga M, Okuma E, Kobayashi H, Wake N, Tsuneyoshi M

    Virchows Arch   2011.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Cytoplasmic and stromal expression of laminin γ 2 chain correlates with infiltrative invasion in ovarian mucinous neoplasms of gastro-intestinal type. Invited Reviewed International journal

    Okuma E, Ohishi Y, Oda Y, Aishima S, Kurihara S, Nishimura I, Yasunaga M, Kobayashi H, Wake N, Tsuneyoshi M.

    Oncol Rep   2010.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Hobnail-like cells in serous borderline tumor do not represent concomitant incipient clear cell neoplasms. Invited Reviewed International journal

    Ohishi Y, Oda Y, Kurihara S, Kaku T, Yasunaga M, Nishimura I, Okuma E, Kobayashi H, Wake N, Tsuneyoshi M.

    Hum Pathol   2009.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Immunohistochemical characterization of mullerian mucinous borderline tumor (MMBT): Possible histogenetic link with serous borderline tumor (SBT) and low-grade endometrioid tumor (LG-ET). Reviewed International journal

    Masafumi Yasunaga1, MD, Yoshihiro Ohishi1, MD, PhD, Yoshinao Oda1, MD, PhD, Munechika Misumi3, MD, PhD, Atsuko Iwasa1, MD, PhD, Shuichi Kurihara1, MD, Izumi Nishimura1, MD, Emi Ohkuma1, MD, Hiroaki Kobayashi2, MD, PhD, Norio Wake2, MD, PhD and Masazumi Tsuneyoshi1, MD, PhD

    Human Pathology   2009.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Mullerian mucinous borderline tumor (MMBT) and gastrointestinal mucinous borderline tumor (IMBT) are considered mucinous tumor subtypes. However, it has been reported that MMBT shares many clinicopathologic features with serous borderline tumor (SBT). Furthermore, some investigators have explained the histogenesis of MMBT by metaplastic and hyperplastic transformation of endometriosis [1].
    The purpose of this study is to substantiate the concept that MMBT is histogenetically closer to SBT or low-grade endometrioid tumors than to IMBT by directly comparing their immunophenotype.
    A total of 80 cases of low-grade ovarian tumors composed of 20 MMBTs, 20 IMBTs, 20 SBTs, and 20 low-grade endometrioid tumors (LG-ETs), were immunohistochemically evaluated for the expression of estrogen receptor (ER), progesterone receptor (PgR), vimentin, WT-1, beta-catenin and PTEN.
    Almost all cases of MMBT, SBT, and LG-ET showed diffuse and strong nuclear expression of ER and PgR. In addition, about half of the MMBT, SBT, and LG-ET cases showed focal but strong vimentin cytoplasmic expression. In contrast, IMBT showed no expression of ER, PgR, or vimentin, except for one case in which ER expression was very focally and weakly observed. Beta-catenin nuclear expression was significantly more frequent in LG-ET than in MMBT, IMBT, or SBT. PTEN expression was significantly lower in LG-ET than in MMBT, IMBT and SBT. Multiple comparisons of quantitative immunoreactivities of ER, PgR, and vimentin revealed that the IMBT expression profiles were significantly different from those of MMBTs, SBTs, and LG-ETs.
    The immunohistochemical expression profiles of ER, PgR, and vimentin substantiate the concept that the histogenesis of MMBT is closer to those of SBT and LG-ET than to that of IMBT. However, aberrant expression of bata-catenin and PTEN gene, both of which are known to contribute the tumorigenesis of LG-ET, appeared to be less important for the tumorigenesis of MMBT.

  • Malignant transformation of mature cystic teratoma to squamous cell carcinoma involves altered expression of p53- and p16/Rb-dependent cell cycle regulator proteins. Invited Reviewed International journal

    Iwasa A, Oda Y, Kurihara S, Ohishi Y, Yasunaga M, Nishimura I, Takagi E, Kobayashi H, Wake N, Tsuneyoshi M.

    Pathol Int.   2008.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Ovarian undifferentiated carcinoma resembling giant cell carcinoma of the lung Reviewed International journal

    安永 昌史, 大石 善丈, 西村　和泉, 田宮 貞史, 岩佐　厚子, 高木　恵美, 井上 貴史, 矢幡 秀昭, 小林 裕明, 和氣 徳夫, 恒吉 正澄

    Pathology International   58   244 - 248   2008.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • 当院における子宮頸癌放射線療法に伴う消化管合併症の検討 Reviewed

    安永 昌史, 松隈　敬太

    日本婦人科腫瘍学会   22 ( 2 )   109 - 114   2004.4

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • 遺伝子解析により出生前診断した致死性骨異形成症の1例 Reviewed

    安永 昌史, 永田 秀昭, 阿萬 紫, 佐藤 昌司, 福嶋 恒太郎, 中並 尚幸, 羽田　明, 中野 仁雄

    日本産科婦人科学会   54 ( 11 )   1514 - 1518   2002.11

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

▼display all

Presentations

▼display all

MISC

  • 子宮内膜癌のゲノム異常と治療法

    安永　昌史

    文光堂   2023.12

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • 【子宮II-子宮体部-】子宮内膜癌のゲノム異常と治療法

    安永 昌史

    病理と臨床   41 ( 12 )   1289 - 1293   2023.12   （ ISSN:0287-3745 ）

    　More details

    Language：Japanese   Publisher：(株)文光堂  

  • 子宮の腫瘍・類腫瘍

    安永　昌史　加藤　聖子

    産科婦人科疾患の最新の治療2022-2024   2021.11

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • 癌の増殖と炎症性サイトカイン

    安永　昌史　加藤　聖子

    別冊Bio Clinica   2017.11

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

    癌の発生及び蔵相、進展には腫瘍細胞と腫瘍周囲微小環境が相互に密接に関係していることが報告されている。腫瘍周囲微小環境を構成する細胞には癌関連線維芽細胞やTumor-Associated Macrophages(TAM)などがあり、これらの細胞と腫瘍細胞は炎症性サイトカインなどの伝達物質を介し、密に関連しながら腫瘍の増殖、進展に促進的に働いている。この関係性を阻害することは、腫瘍の増殖、進展に抑制的に働くと考えられ、今後のがん治療の標的の一つとされている。

  • 子宮体癌・子宮内膜増殖症

    安永　昌史　加藤　聖子

    1336専門家による私の治療　2017-18年度版   2017.7

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

Professional Memberships

  • Japanese Society of Clinical Cytology

  • 日本婦人科腫瘍学会

  • Japan Society of Obstetrics and Gynecology

  • 日本婦人科内視鏡学会

Committee Memberships

  • 日本臨床細胞学会   Councilor   Domestic

    2023.6 - 2025.6   

  • JCOG   施設コーディネーター  

    2019.4 - 2021.3   

Academic Activities

  • Screening of academic papers

    Role(s)： Peer review

    2024

    　More details

    Type：Peer review 

    Number of peer-reviewed articles in foreign language journals：1

  • Screening of academic papers

    Role(s)： Peer review

    2023

    　More details

    Type：Peer review 

    Number of peer-reviewed articles in foreign language journals：1

  • ポスター座長

    第74回日本産科婦人科学会学術講演会  （ Japan ） 2022.8 - 2023.8

    　More details

    Type：Competition, symposium, etc. 

  • Screening of academic papers

    Role(s)： Peer review

    2022

    　More details

    Type：Peer review 

    Number of peer-reviewed articles in foreign language journals：2

  • Screening of academic papers

    Role(s)： Peer review

    2021

    　More details

    Type：Peer review 

    Number of peer-reviewed articles in foreign language journals：3

  • Screening of academic papers

    Role(s)： Peer review

    2020

    　More details

    Type：Peer review 

    Number of peer-reviewed articles in foreign language journals：1

  • 座長

    第 158 回 福岡産科婦人科学会  （ Japan ） 2019.1

    　More details

    Type：Competition, symposium, etc. 

  • Screening of academic papers

    Role(s)： Peer review

    2019

    　More details

    Type：Peer review 

    Number of peer-reviewed articles in foreign language journals：1

  • Screening of academic papers

    Role(s)： Peer review

    2018

    　More details

    Type：Peer review 

    Number of peer-reviewed articles in Japanese journals：1

▼display all

Research Projects

  • 重粒子線がん治療婦人科腫瘍検討班

    2018.6

    　 More details

    Authorship：Coinvestigator(s) 

  • 腫瘍の浸潤・転移に関係していると言われる腫瘍周囲間質に着目し、子宮頸癌症例において、同間質内で特異的に発現が増減している物質の探索により、子宮頸癌のリンパ節転移の予測マーカーとなるかどうかを明らかにすること。

    2017 - 2019

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    　 More details

    Authorship：Principal investigator  Grant type：Scientific research funding

Educational Activities

  • 臨床においてはレジデントの臨床教育・手術指導などを行い、学会発表、論文作成の援助を行っている。
    大学において医歯薬合同の臨床医学IV-①の授業で[女性生殖器の良性疾患と悪性疾患]の講義を行っている。
    また医学部生に対し、泌尿・生殖器の授業で[付属器腫瘍（良性～悪性）]の講義を行っている。

Class subject

  • 付属器悪性腫瘍

    2022.10 - 2023.3   Second semester

Other educational activity and Special note

  • 2022  Class Teacher  学部

  • 2017  Special Affairs  医歯薬合同の腎・泌尿生殖器概論の講義を担当。 医学部3年生の泌尿。生殖器の後期講義を担当。

    　詳細を見る

    医歯薬合同の腎・泌尿生殖器概論の講義を担当。
    医学部3年生の泌尿。生殖器の後期講義を担当。

Outline of Social Contribution and International Cooperation activities

  • 子宮がん検診の施行、子宮頸がん検診の細胞診診断などの診療を通じて、公共の健康を守る活動に従事している。

Travel Abroad

  • 2020.1

    Staying countory name 1：Thailand   Staying institution name 1：シリラート病院

  • 2019.2

    Staying countory name 1：Thailand   Staying institution name 1：シリラート病院

Specialized clinical area

  • Biology / Medicine, Dentistry and Pharmacy / Surgical Clinical Medicine / Obstetrics and Gynecology

Clinician qualification

  • Specialist

    Japan Society of Obstetrics and Gynecology（JSOG）

  • Specialist

    The Japan Society of Gynecologic Oncology

  • Specialist

    The Japanese Society of Clinical Cytology

Year of medical license acquisition

  • 2000

Notable Clinical Activities

  • H31年度・令和元年度からは病棟医長として入退院患者の管理・レジデントの臨床教育及び学会発表の援助等を行っている。 令和2年においては、臨床データを使用し、論文の作成、及びレジデントの症例報告の論文作成の援助を行った。 令和4年度からは、医局長として、医局の運営に携わっている。